Linked Life Data

7536097

Source:http://linkedlifedata.com/resource/pubmed/id/7536097

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7536097rdf:typepubmed:Citationlld:pubmed
pubmed-article:7536097lifeskim:mentionsumls-concept:C0007289lld:lifeskim
pubmed-article:7536097lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:7536097lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:7536097lifeskim:mentionsumls-concept:C0087140lld:lifeskim
pubmed-article:7536097lifeskim:mentionsumls-concept:C0581621lld:lifeskim
pubmed-article:7536097lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:7536097lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:7536097lifeskim:mentionsumls-concept:C0301630lld:lifeskim
pubmed-article:7536097lifeskim:mentionsumls-concept:C1373060lld:lifeskim
pubmed-article:7536097lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:7536097lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:7536097pubmed:issue1lld:pubmed
pubmed-article:7536097pubmed:dateCreated1995-5-17lld:pubmed
pubmed-article:7536097pubmed:abstractText1. Three hours after intraplantar carrageenin (6 mg/150 microliters of saline) Fos-like immunoreactivity (Fos-LI) was mainly observed in L4 and L5 segments of the dorsal horn. Both superficial (I-II) and deep laminae (V-VI) neurones were labelled. 2. We have studied the effect of systemic administration of a nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester (L-NAME) on carrageenin evoked c-Fos expression and thus the contribution of nitric oxide to this expression. 3. Pre-administration of L-NAME (10, 25, 50, 100 mg kg-1, i.v.) dose-dependently reduced the number of superificial and deep laminae Fos-LI neurones, 100 mg kg-1 produced a 63 +/- 2% and 72 +/- 4% reduction of Fos-LI neurones respectively, P < 0.0001 for both superficial and deep neurones. 4. Pre-administered L-NAME dose-relatedly reduced the carrageenin-evoked paw and ankle oedema, with 100 mg kg-1 of L-NAME resulting in a 74 +/- 2% and 103 +/- 2% reduction respectively. 5. Post-administration of L-NAME (10 mg kg-1, i.v.) reduced the number of superficial and deep laminae Fos-LI neurones (65 +/- 7% and 53 +/- 8% reduction respectively, P < 0.01 for both superficial and deep neurones). 6. Post-administered L-NAME reduced both the paw and ankle oedema (52 +/- 8% and 62 +/- 10% reduction respectively, P < 0.0001 for both paw and ankle). 7. Pre-administered D-NAME (100 mg kg-1, i.v.), the inactive isomer of L-NAME, produced a weak reduction of the number of superficial laminae Fos-LI neurones (26 +/- 8% reduction, P<0.05), without influencing the deep Fos-LI neurones (5 +/- 8% enhancement) or the oedema.8. Systemic L-arginine (1200 mg kg-1) did not reverse the reduction of the total number of Fos-LI neurones induced by 100mg kg-1 of L-NAME, or the effect of L-NAME on the paw and ankle oedema.9. Intraplantar L-arginine (30 mg) did not reverse the effect of L-NAME (100 mg kg-1) on the total number of Fos-LI neurones. However, the inhibitory effects of L-NAME on the paw and ankle oedema were partially reversed by intraplantar L-Arginine (34 +/- 9% and 45 +/- 11% reduction of carrageenin oedema respectively) with these effects being significant as compared to the effect of L-NAME alone(P<0.05 for both).10. There is a strong correlation between the reduction of the number of Fos-LI neurones and the oedema by L-NAME, clearly demonstrating a predominant role of peripheral NO in the development of one of the signs of carrageenin inflammation.lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:languageenglld:pubmed
pubmed-article:7536097pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:citationSubsetIMlld:pubmed
pubmed-article:7536097pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7536097pubmed:statusMEDLINElld:pubmed
pubmed-article:7536097pubmed:monthJanlld:pubmed
pubmed-article:7536097pubmed:issn0007-1188lld:pubmed
pubmed-article:7536097pubmed:authorpubmed-author:BessonJ MJMlld:pubmed
pubmed-article:7536097pubmed:authorpubmed-author:ChapmanVVlld:pubmed
pubmed-article:7536097pubmed:authorpubmed-author:HonourJJlld:pubmed
pubmed-article:7536097pubmed:authorpubmed-author:BuritovaJJlld:pubmed
pubmed-article:7536097pubmed:issnTypePrintlld:pubmed
pubmed-article:7536097pubmed:volume114lld:pubmed
pubmed-article:7536097pubmed:ownerNLMlld:pubmed
pubmed-article:7536097pubmed:authorsCompleteYlld:pubmed
pubmed-article:7536097pubmed:pagination77-84lld:pubmed
pubmed-article:7536097pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:7536097pubmed:meshHeadingpubmed-meshheading:7536097-...lld:pubmed
pubmed-article:7536097pubmed:meshHeadingpubmed-meshheading:7536097-...lld:pubmed
pubmed-article:7536097pubmed:meshHeadingpubmed-meshheading:7536097-...lld:pubmed
pubmed-article:7536097pubmed:meshHeadingpubmed-meshheading:7536097-...lld:pubmed
pubmed-article:7536097pubmed:meshHeadingpubmed-meshheading:7536097-...lld:pubmed
pubmed-article:7536097pubmed:meshHeadingpubmed-meshheading:7536097-...lld:pubmed
pubmed-article:7536097pubmed:meshHeadingpubmed-meshheading:7536097-...lld:pubmed
pubmed-article:7536097pubmed:meshHeadingpubmed-meshheading:7536097-...lld:pubmed
pubmed-article:7536097pubmed:meshHeadingpubmed-meshheading:7536097-...lld:pubmed
pubmed-article:7536097pubmed:meshHeadingpubmed-meshheading:7536097-...lld:pubmed
pubmed-article:7536097pubmed:meshHeadingpubmed-meshheading:7536097-...lld:pubmed
pubmed-article:7536097pubmed:meshHeadingpubmed-meshheading:7536097-...lld:pubmed
pubmed-article:7536097pubmed:meshHeadingpubmed-meshheading:7536097-...lld:pubmed
pubmed-article:7536097pubmed:meshHeadingpubmed-meshheading:7536097-...lld:pubmed
pubmed-article:7536097pubmed:year1995lld:pubmed
pubmed-article:7536097pubmed:articleTitleReduction of carrageenin oedema and the associated c-Fos expression in the rat lumbar spinal cord by nitric oxide synthase inhibitor.lld:pubmed
pubmed-article:7536097pubmed:affiliationPhysiopharmacologie du Systme Nerveux, INSERM U.161, Paris, France.lld:pubmed
pubmed-article:7536097pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7536097pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7536097lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7536097lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7536097lld:pubmed